BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Blogs » BioWorld MedTech Perspectives » Ultrasound patch could aid in patient healing

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Ultrasound patch could aid in patient healing

Aug. 9, 2013
By Omar Ford

WolverineMarvel Comics' popular character Wolverine is known for his ability to heal from nearly any wound. Researchers at Drexel University in Philadelphia have developed an ultrasound technology aimed at giving patients who suffer from chronic wounds, an extra boost in recovering from the injuries.

And while it's not anywhere near the level of Wolverine's powers (he is a fictional character after all), initial studies show promising results for the device. In the study, researchers treated patients suffering from venous ulcers, which account for 80% of all chronic wounds found on lower extremities and affect approximately 500,000 U.S. patients annually, a number that’s expected to increase as obesity rates climb. It’s estimated that treatment for venous ulcers costs the U.S. healthcare system over $1 billion dollars per year.

Researchers applied the device to patients for 15 to 45 minutes, once a week, while they were seeing their physician for a routine appointment. The end results was improved healing compared to the control group that did not receive treatment.

I interviewed some of the researchers involved in this project, and while there are definite plans to try and get this technology into the market place, there is also a sense of urgency.

Joshua Samuels, one of the researchers in the study spoke passionately about the technology and perhaps gave one of the most heartfelt interviews that I have had in my six years here at Medical Device Daily. I think his quote pretty much sums up the pure unbridled mission of med-tech.

“It’s always slow moving getting it from the research lab to the market place,” Samuels said. “What I would really like to see is the device get used by patients as quick as possible. It’s always tough when you do biomedical research knowing that it could take six to seven years to get onto the market place. I know that there are regulations and I know that everything has to go through its due process, but that’s something I would really like to see – to get to patients so that it can help them.”

Here's hoping that happens.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing